A few years ago, both Pfizer (PFE -0.11%) and Moderna (MRNA -3.64%) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer sold a COVID treatment too -- and these products generated billions of dollars in earnings for the companies.Pfizer and Moderna still sell these top products, but demand for them has declined as we head toward a post-pandemic world. That's weighed on earnings, pushed the companies to cut costs to match infrastruct ...

Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companies for a good price and hold onto the shares for a number of years -- giving those companies time to bring products to market and grow earnings. And that should boost share performance over time.This week, Wood has been adding to her positions i ...

In the latest market close, Moderna (MRNA) reached $104.26, with a +0.39% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.82%.The the stock of biotechnology company has risen by 17.52% in the past month, leading the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.Market participants will be closely following the financial results o ...

When a stock falls out of favor with the general investment community, famous investor Cathie Wood often gives it a second look -- and if the company happens to be an innovator with great long-term potential, she'll jump right in. This strategy has worked for the chief executive officer of Ark Invest, helping her to scoop up top quality players for bargain prices.Last year, Wood's benchmark Ark Innovation fund climbed 67%, beating the S&P 500. But that may be just the beginning. Wood counts on holding onto ...

Now might be a great time for investors to consider investing in precision medicine stocks. For those who don’t know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient. It aims to provide the right treatment at the right time for the right person. This may reduce complications for the individual.Precision medicine stocks today are companies with high potential growth prospects within the healthcare sector. I’m interested in this in ...

INDIA - 2024/02/10: In this photo illustration, a Moderna logo is seen displayed on a smartphone. ... [+] (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesModerna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier study, a combination of the vaccine and Merck’s blockbuster Keytruda immunotherapy resulted i ...

Moderna (MRNA -1.38%) shot to stardom in the early days of the pandemic as it brought its coronavirus vaccine from drawing board to commercialization in less than a year -- and then went on to generate billions of dollars in earnings. The shares soared more than 2,000% in about a year and a half, and investors couldn't get enough of this vaccine innovator.But as vaccine demand declined in later stages of the pandemic, Moderna's revenue followed, and investors worried about the company's earnings down the ro ...

Moderna, Inc. (NASDAQ:MRNA) Barclays 26th Annual Global Healthcare Conference Call March 12, 2024 2:35 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head, Investor Relations Conference Call Participants Gena Wang - Barclays Gena Wang Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover SMID cap biotech. It is my great pleasure to introduce our next presenting company, Moderna. With us today, we have Lavina Talukdar, SVP, Head of Investor Relations. Questio ...

Shares of Moderna (MRNA) rose 8.7% on Mar 11, after a government website posted details of the initiation of a phase II/III study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. The therapy is being developed in collaboration with Merck (MRK) .The phase II/III study (called INTerpath-007) will evaluate the safety and efficacy of mRNA-4157, combined with Merck’s blockbuster immuno-oncology drug K ...

Moderna (MRNA) shares soared 8.7% in the last trading session to close at $111.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.9% gain over the past four weeks.Share price rose after a government website posted details of initiation of a phase II/III study on mRNA-4157/V940, Moderna’s investigational individualized neoantigen therapy (INT), in patients with cutaneous squamous cell carcinoma (CSCC), a form of skin cancer. T ...